Q-omics provides the consensus-scored LINC02586 profile across patient tissues and cancer cell-line models. LINC02586 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02586 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LINC02586 RNA expression shows 13,209 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where LINC02586 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02586 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02586 survival associations across molecular data types. LINC02586 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02586 RNA expression–survival associations across cancer types. High LINC02586 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, OV, HNSC, CESC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02586 RNA expression.
This table summarizes LINC02586 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02586. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02586 shows lower tumor expression in KIRC, KICH, KIRP, LUAD and BRCA and higher tumor expression in COAD. The KIRC box plot shows higher LINC02586 RNA expression in normal versus tumor tissue (log2 FC = −1.058, t-test p < 0.001).
This table shows molecular features associated with LINC02586 in patient tissues and cancer cell lines. In patient samples, LINC02586 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
